vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and MEXCO ENERGY CORP (MXC). Click either name above to swap in a different company.

MEXCO ENERGY CORP is the larger business by last-quarter revenue ($1.4M vs $1.4M, roughly 1.0× FATE THERAPEUTICS INC). On growth, FATE THERAPEUTICS INC posted the faster year-over-year revenue change (-26.4% vs -26.8%). Over the past eight quarters, MEXCO ENERGY CORP's revenue compounded faster (-12.2% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Mexco Energy Corp is an independent upstream energy firm focused on the exploration, development, acquisition, and production of crude oil, natural gas, and natural gas liquids. It operates primarily across onshore U.S. basins including the Permian Basin and Gulf Coast, serving domestic energy markets.

FATE vs MXC — Head-to-Head

Bigger by revenue
MXC
MXC
1.0× larger
MXC
$1.4M
$1.4M
FATE
Growing faster (revenue YoY)
FATE
FATE
+0.4% gap
FATE
-26.4%
-26.8%
MXC
Faster 2-yr revenue CAGR
MXC
MXC
Annualised
MXC
-12.2%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
FATE
FATE
MXC
MXC
Revenue
$1.4M
$1.4M
Net Profit
$50.2K
Gross Margin
Operating Margin
6.6%
Net Margin
3.6%
Revenue YoY
-26.4%
-26.8%
Net Profit YoY
37.9%
-89.3%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
MXC
MXC
Q4 25
$1.4M
$1.4M
Q3 25
$1.7M
$1.7M
Q2 25
$1.9M
$1.8M
Q1 25
$1.6M
$2.0M
Q4 24
$1.9M
$1.9M
Q3 24
$3.1M
$1.7M
Q2 24
$6.8M
$1.7M
Q1 24
$1.9M
$1.8M
Net Profit
FATE
FATE
MXC
MXC
Q4 25
$50.2K
Q3 25
$-32.3M
$323.5K
Q2 25
$-34.1M
$242.0K
Q1 25
$-37.6M
$635.0K
Q4 24
$469.1K
Q3 24
$-47.7M
$317.2K
Q2 24
$-38.4M
$291.0K
Q1 24
$-48.0M
$264.3K
Operating Margin
FATE
FATE
MXC
MXC
Q4 25
6.6%
Q3 25
-1995.1%
20.9%
Q2 25
-1938.5%
18.3%
Q1 25
-2534.1%
36.1%
Q4 24
23.6%
Q3 24
-1703.9%
23.4%
Q2 24
-665.7%
21.8%
Q1 24
-2652.9%
24.5%
Net Margin
FATE
FATE
MXC
MXC
Q4 25
3.6%
Q3 25
-1852.4%
18.6%
Q2 25
-1786.6%
13.3%
Q1 25
-2309.5%
31.9%
Q4 24
24.8%
Q3 24
-1551.0%
18.1%
Q2 24
-567.4%
16.8%
Q1 24
-2493.7%
14.7%
EPS (diluted)
FATE
FATE
MXC
MXC
Q4 25
$0.02
Q3 25
$-0.27
$0.16
Q2 25
$-0.29
$0.12
Q1 25
$-0.32
$0.30
Q4 24
$0.22
Q3 24
$-0.40
$0.15
Q2 24
$-0.33
$0.14
Q1 24
$-0.47
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
MXC
MXC
Cash + ST InvestmentsLiquidity on hand
$203.7M
$2.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$19.3M
Total Assets
$318.9M
$20.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
MXC
MXC
Q4 25
$203.7M
$2.3M
Q3 25
$215.4M
$2.7M
Q2 25
$222.8M
$2.5M
Q1 25
$240.4M
$1.8M
Q4 24
$279.1M
$910.0K
Q3 24
$296.9M
$1.6M
Q2 24
$304.9M
$2.5M
Q1 24
$121.3M
$2.5M
Stockholders' Equity
FATE
FATE
MXC
MXC
Q4 25
$207.2M
$19.3M
Q3 25
$234.1M
$19.2M
Q2 25
$261.4M
$18.8M
Q1 25
$288.4M
$18.7M
Q4 24
$318.7M
$18.0M
Q3 24
$362.3M
$17.5M
Q2 24
$397.0M
$17.7M
Q1 24
$426.1M
$17.6M
Total Assets
FATE
FATE
MXC
MXC
Q4 25
$318.9M
$20.6M
Q3 25
$343.7M
$20.6M
Q2 25
$371.6M
$20.6M
Q1 25
$398.7M
$20.3M
Q4 24
$440.7M
$19.5M
Q3 24
$495.0M
$19.3M
Q2 24
$528.8M
$19.4M
Q1 24
$569.9M
$19.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
MXC
MXC
Operating Cash FlowLast quarter
$-106.1M
$863.3K
Free Cash FlowOCF − Capex
$-112.0M
FCF MarginFCF / Revenue
-8183.9%
Capex IntensityCapex / Revenue
434.8%
Cash ConversionOCF / Net Profit
17.18×
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
MXC
MXC
Q4 25
$-106.1M
$863.3K
Q3 25
$-24.4M
$704.3K
Q2 25
$-24.6M
$1.4M
Q1 25
$-33.8M
$1.3M
Q4 24
$-122.9M
$934.7K
Q3 24
$-29.4M
$927.8K
Q2 24
$-32.3M
$1.1M
Q1 24
$-33.4M
$1.1M
Free Cash Flow
FATE
FATE
MXC
MXC
Q4 25
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
MXC
MXC
Q4 25
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
MXC
MXC
Q4 25
434.8%
Q3 25
126.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
Q2 24
0.8%
Q1 24
4.5%
Cash Conversion
FATE
FATE
MXC
MXC
Q4 25
17.18×
Q3 25
2.18×
Q2 25
5.63×
Q1 25
2.09×
Q4 24
1.99×
Q3 24
2.92×
Q2 24
3.71×
Q1 24
4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FATE
FATE

Segment breakdown not available.

MXC
MXC

Oil Sales$1.1M79%
Other$285.1K21%

Related Comparisons